SCHEMBL6447202

SCHEMBL6447202

O=C(Nc1ccc(Cl)cc1)c1ccc(C(=O)Nc2nnc(-c3cc(Cl)cc(Cl)c3O)s2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.46
MAPT P10636 2/20 0.46
MAPK1 P28482 2/20 0.46
NT5E P21589 1/20 0.46
THRB P10828 1/20 0.46
MEN1 O00255 4/20 0.46
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HTT P42858 1/20 0.46
BLM P54132 1/20 0.46
MCL1 Q07820 1/20 0.46
POLB P06746 1/20 0.45
ABL1 P00519 2/20 0.44
SRC P12931 2/20 0.44
PTGER3 P43115 1/20 0.44
PTGS1 P23219 1/20 0.44
TBXAS1 P24557 1/20 0.44
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6446020 0.96 KMT2A (0.48) KMT2AMAPTTHRBMEN1RAB9A
SCHEMBL6445978 0.94 SNCA (0.47) KMT2AMAPK1MEN1RAB9ANPC1
SCHEMBL6447053 0.93 CSNK2A2 (0.49) KMT2AMAPTMEN1RAB9ANPC1
SCHEMBL6445760 0.93 CSNK2A2 (0.52) KMT2AMAPTMEN1RAB9ANPC1
SCHEMBL6445816 0.92 BCAT2 (0.49) KMT2AMAPTMAPK1MEN1RAB9A
SCHEMBL6444242 0.92 RAB9A (0.52) KMT2AMAPTMEN1RAB9ANPC1
SCHEMBL6445872 0.92 NPC1 (0.53) KMT2AMAPTTHRBMEN1RAB9A
SCHEMBL6444705 0.91 MAPK1 (0.57) KMT2AMAPTMAPK1MEN1RAB9A
SCHEMBL6449238 0.90 CSNK2A2 (0.52) KMT2AMAPTMEN1RAB9ANPC1
SCHEMBL6445643 0.90 CSNK2A2 (0.46) KMT2AMAPTMEN1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US claimed
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 BRISTOL-MYERS SQUIBB COMPANY 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143384-A1 Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 SERPINE1, SERPINC1, SERPINB1 KMT2A 3566/4885MAPT 3346/4885MAPK1 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.